Patients treated with biologic drugs for various-not only dermatological-diseases are growing in number. Biologic drugs applied as a long-term therapy of psoriasis are safe, enable disease remission, and most importantly, help improve the patient's quality of life. It is also crucial to note, that biologic agents decrease patient mortality rate. Much research has shown the unquestionable efficiency of biologic therapies despite their also well-documented rare adverse effects. Due to the growing range of application of these agents, it is critical to keep an observant eye during the monitoring of the patient in case of new disease activity. This study aims to present the case of a female patient treated with etanercept for severe psoriasis arthritis (PsA) who subsequently developed acute sarcoidosis and to examine the risk of serious adverse events.
ObjectivesTo establish the relationship between cutaneous involvement and Quality of Life (QoL) in patients with systemic lupus erythematosusMethodsCross-sectional study of SLE patients with cutaneous involvement, fulfilling SLICC/ACR 2012 classification criteria. Cutaneous involvement was assessed by Cutaneous Lupus Erithematosus Disease Area and Severity Index (CLASI), disease activity – by SLEDAI and SLAM and QoL by SF-8 questionnaire. The Pearson correlation coefficient was calculated between the variables.ResultsThe study included 92 Caucasian SLE female patients with a mean age of 40,0±12,6 yrs and a mean disease duration of 5,1±5,8 yrs. The mean age at the disease onset was 33,5±11,4 yrs and the mean SLICC/ACR criteria number – 6,1±2,8 points. The disease activity by SLEDAI and SLAM was appreciated as high with 1,24±10,4 and 12,1±8,6 points, respectively. The SLICC/ACR DI constituted 1,47±1,6 points. The cutaneous involvment by CLASI showed a mean activity of 4,7 points and a damage of 3,0 points, mean CLASI score being appreciated with 7,2 points. The QoL by SF-8 demonstrated low indices, compared to general population, in both domains: Physical Component Summary (PCS) and Mental Component Summary (MCS) with a mean value of 37,74 and 38,72 points, respectively. The analysis of Pearson coefficient between the QoL and CLASI did not show significant correlation (r≤0,2, p>0,05). The PCS og the QoL correlated inversely with the disease activity (r=-0,58 for SLAM and r=-0,45 for SLEDAI, p<0,05) and the MCS correlated inversely with SLICC/ACR classificatino criteria (r=-0,45, p<0,05). CLASI activity index correlated with SLAM and SLEDAI (r=0,45 for SLAM and r=0,37 for SLEDAI).ConclusionsThe QoL is dicreased in SLE patients by both components: physical and mental. The severity of cutaneous involvment did not correlate with the QoL's indices. Meantime, CLASI activity score correlated with disease activity and the MCP pf the QoL correlated with the number of SCLICC/ACR 2012 classification criteria.Disclosure of InterestNone declared
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.